CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

Hello and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that ...

Welcome to the Viking Therapeutics Fourth Quarter and ... Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that ...

Viking Therapeutics reports quarterly losses ... and extremely productive year for Viking,” stated Brian Lian, Ph.D., CEO of Viking. “During the year, the company reported positive data ...

Viking held cash, cash equivalents and short-term investments of $903M, compared to $362M as of December 31, 2023. 2024 ...

In other Viking Therapeutics news, CEO Brian Lian sold 194,490 shares of Viking Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $42.75 ...

Viking Therapeutics (NASDAQ:VKTX – Free Report) had its target price lowered by Maxim Group from $120.00 to $70.00 in a research note issued to investors on Friday morning,Benzinga reports.

In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other stocks that took a nosedive in January. Historically, the S&P 500’s performance ...

Hello and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that comments ...

SAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Viking Therapeutics ... productive year for Viking," stated Brian Lian, Ph.D., chief executive officer of Viking. "During the year, the company reported ...